Neurosense Therapeutics Ltd
Change company Symbol lookup
Select an option...
NRSN Neurosense Therapeutics Ltd
ST Sensata Technologies Holding PLC
ZTS Zoetis Inc
CRM Salesforce Inc
IVR-C Invesco Mortgage Capital Inc
MSM MSC Industrial Direct Co Inc
BLUE bluebird bio Inc
ENSV Enservco Corp
ULIHF United Laboratories International Holdings Ltd

Based in Israel
Company profile

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Closing Price
Day's Change
-0.21 (-6.36%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
June 30, 2022
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study

-- Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease -- CogniC is expected to advance into clinical trials in 2023 NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing...(PR Newswire)

June 28, 2022
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027 News Commentary Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors such as the increasing prevalence and incidence of pancreatic...(PR Newswire)

June 27, 2022
Thinking about buying stock in Neurosense Therapeutics, Boxed, Snap, RealReal, or Accelerate Diagnostics?

InvestorsObserver issues critical PriceWatch Alerts for NRSN, BOXD, SNAP, REAL, and AXDX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

-- Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in...(PR Newswire)

June 22, 2022
NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's panel discussion on Innovations in ALS: Exploring New...(PR Newswire)

June 01, 2022
NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

-- Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers -- PrimeC has Orphan Drug Designation with the FDA and EMA (PR Newswire)

May 31, 2022
NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2022 and provided a business update. (PR Newswire)

May 23, 2022
NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022

-- Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS" -- Phase IIb ALS study for NeuroSense's combination therapy PrimeC expected to commence Q2 2022 (PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.